On March 31, 2025, in the U.S. District Court for the Eastern District of Texas vacated the Food and Drug Administration’s (FDA) final rule, in which FDA attempted to assert regulatory authority over laboratory-developed tests (LDT) as “devices” under the Food, Drug, and Cosmetic Act (FDCA).